Recent Updates — INBP

Integrated BioPharma reported fiscal year and quarterly results for the period ended June 30, 2026. Fiscal year revenue decreased 19.3% to $48.9 million from $54.4 million, with an operating loss of $2.7 million compared to prior-year income of $2.0 million. Net loss widened to $2.8 million ($0.09 per share) from net income of $0.8 million ($0.03 per share). For the quarter ended June 30, 2026, revenue fell 31% to $9.8 million from $14.2 million, resulting in an operating loss of $0.9 million and a net loss of $1.4 million ($0.04 per share). The company operates in the nutraceutical industry, manufacturing and distributing vitamins, supplements, and herbal products.